Detalles de la búsqueda
1.
Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
Diabetes Ther
; 10(6): 2201-2217, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31606880
2.
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Diabetes Res Clin Pract
; 146: 240-250, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30391333
3.
Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.
Kidney Blood Press Res
; 30(5): 314-22, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17671394
4.
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
J Diabetes Complications
; 27(3): 268-73, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23276620
5.
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Diabetes Technol Ther
; 13(12): 1219-27, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21854192
6.
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
Atherosclerosis
; 197(1): 400-6, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17727860
7.
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.
Curr Control Trials Cardiovasc Med
; 6(1): 9, 2005 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-15910680
8.
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Eur Heart J
; 26(24): 2664-72, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16143705
Resultados
1 -
8
de 8
1
Próxima >
>>